Loading data
DRUGNasdaq
| Unit: CAD | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Research and development expense | 11.08 m CAD | 1.18 m CAD | 5 m CAD | 12.18 m CAD |
| Income tax expense | 0 CAD | 0 CAD | 0 CAD | 0 CAD |
| Net income (reported basis) | -12.23 m CAD | -2.8 m CAD | -7.37 m CAD | -14.96 m CAD |
| Basic earnings per share | -1.78 CAD/share | -0.65 CAD/share | -1.98 CAD/share | -6.06 CAD/share |
| Diluted earnings per share | — | -0.65 CAD/share | -1.98 CAD/share | -6.06 CAD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.